AM Best to Host Webinar on Best’s Impairment Study 2018

OLDWICK, N.J.--(BUSINESS WIRE)-- AM Best analysts will review the results published in "Best’s Impairment Rate and Rating Transition Study—1977 to 2018," during a webinar on Tuesday, June 18, 2019, at 10 a.m. (EDT). Panelists will review the impairment rates and ratings transitions based on both the financial strength rating (FSR) and the long-term issuer credit rating (ICR) scales, which are most familiar to users of debt market ratings.

In addition, panelists will address issues related to comparing AM Best impairment studies to default/impairment studies of other National Recognized Statistical Ratings Organizations (NRSRO). They will explain how comparisons between AM Best’s impairment studies and the corporate default studies of other NRSROs should be based on AM Best’s holding company ICRs or their proxies, which are effectively equivalent to AM Best’s senior unsecured debt ratings.

Register at: http://www.ambest.com/webinars/impairment19

Panelists include:

• Emmanuel Modu, managing director, AM Best; and
• Michael Porcelli, director, AM Best.

Attendees can submit questions during registration or by emailing [email protected]. The event will be streamed in video and audio formats, and playback will be available to registered viewers shortly after the event.

AM Best is a trusted source of insurance market insight and data, and the only global credit rating agency with a unique focus on the insurance industry. Best's Credit Ratings are a recognized indicator of insurer financial strength and creditworthiness. Visit http://www.ambest.com for more information.

Copyright © 2019 by A.M. Best Company, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005956/en/

Emmanuel Modu
Managing Director
+1 908 439 2200, ext. 5356
[email protected]

Source: AM Best

You May Also Be Interested In

• FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
• The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
• Modern Preppy Revival: COOFANDY Brings Relaxed Collegiate Style to Men’s Everyday Wardrobe